Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

MHC class II in lung cancer

Date

09 Oct 2016

Session

Basic science and translational research

Presenters

Yayi He

Citation

Annals of Oncology (2016) 27 (6): 15-42. 10.1093/annonc/mdw363

Authors

Y. He1, L. Rozeboom2, R. Dziadziuszko3, C.J. Rivard2, K. Ellison2, H. Yu2, C. Zhou1, F. Hirsch4

Author affiliations

  • 1 Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, 200000 - Shanghai/CN
  • 2 Medical Oncology, University of Colorado Denver, Denver/US
  • 3 Dept. Of Oncology And Radiotherapy, Medical University of Gdansk, Gdansk/PL
  • 4 Medical Oncology, University of Colorado Denver, 80247 - Denver/US
More

Resources

Abstract 2599

Background

Immunotherapy is a recent hotspot in lung cancer research. The ability of the immune system to recognize tumor cells as foreign is restricted through the expression of certain cell-surface molecules such as the major histocompatibility complex (MHC) molecules. The alteration in MHC class II antigens is an event that occurs frequently on primary and metastatic cancer. Therefore, we described the expression of MHC class II in lung cancer cell lines and patient tissues.

Methods

We studied MHC II (DP, DQ, DR) (CR3/43, Abcam) protein expression in 55 non-small cell lung cancer (NSCLC) cell lines, 42 small cell lung cancer (SCLC) cell lines and 278 lung cancer patient tissues by immunohistochemistry (IHC).

Results

Seven (12.7%) NSCLC cell lines were positive for MHC class II. No SCLC cell lines were found to be MHC II positive. MHC class II was detected in 139 lung cancer samples from the Hirsch Lab. Twenty-one (31.3%) samples stained positive for MHC class II on tumor cells, and 38 (56.7%) had positive MHC class II expression on tumor infiltration lymphocytes (TILs) in NSCLC. There was no positive MHC class II staining on SCLC tumor cells. MHC class II on TILs in SCLC was significant lower than MHC II on TILs in NSCLC (P 

Conclusions

MHC class II was expressed in both NSCLC cell lines and tissues. However, MHC class II was absent in SCLC cell lines and tissue tumor cells. Loss of expression of MHC II on SCLC tumor cells may be a means of escaping anti-cancer immunity. MHC class II expression on TILs was correlated with good prognosis in NSCLC patients.

Clinical trial identification

N/A

Legal entity responsible for the study

Yayi He

Funding

This project was supported by IASLC Young Investigator Award, the Pia and Fred R. Hirsch Endowed Chair at the University of Colorado, and Young Program of Shanghai Health Bureau.

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings